BACKGROUND: Valspodar, a non-immunosuppressive analog of cylosporine, is a potent P-glycoprotein (MDR1) inhibitor. As MDR1-mediated efflux of chemotherapeutic agents from leukemic blasts may contribute to drug resistance, a phase 1 study of valspodar combined with mitoxantrone and etoposide in pediatric patients with relapsed or refractory leukemias was performed. PROCEDURE: Patients received a valspodar-loading dose (2 mg/kg) followed by a 5-day continuous valspodar infusion (8, 10, 12.5, or 15 mg/kg/day) combined with lower than standard doses of mitoxantrone and etoposide. The valspodar dose was escalated using a standard 3 + 3 phase I design. RESULTS: Twenty-one patients were evaluable for toxicity and 20 for response. The maximum tolerated dose (MTD) of valspodar was 12.5 mg/kg/day, combined with 50% dose-reduced mitoxantrone and etoposide. The clearance of mitoxantrone and etoposide was decreased by 64% and 60%, respectively, when combined with valspodar. Dose-limiting toxicities included stomatitis, ataxia, and bone marrow aplasia. Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response. In vitro studies demonstrated P-glycoprotein expression on the blasts of 5 of 14 patients, although only 1 had inhibition of rhodamine efflux by valspodar. CONCLUSIONS: While this regimen was tolerable, responses in this heavily pretreated population were limited to a subset of patients with ALL.
BACKGROUND:Valspodar, a non-immunosuppressive analog of cylosporine, is a potent P-glycoprotein (MDR1) inhibitor. As MDR1-mediated efflux of chemotherapeutic agents from leukemic blasts may contribute to drug resistance, a phase 1 study of valspodar combined with mitoxantrone and etoposide in pediatric patients with relapsed or refractory leukemias was performed. PROCEDURE: Patients received a valspodar-loading dose (2 mg/kg) followed by a 5-day continuous valspodar infusion (8, 10, 12.5, or 15 mg/kg/day) combined with lower than standard doses of mitoxantrone and etoposide. The valspodar dose was escalated using a standard 3 + 3 phase I design. RESULTS: Twenty-one patients were evaluable for toxicity and 20 for response. The maximum tolerated dose (MTD) of valspodar was 12.5 mg/kg/day, combined with 50% dose-reduced mitoxantrone and etoposide. The clearance of mitoxantrone and etoposide was decreased by 64% and 60%, respectively, when combined with valspodar. Dose-limiting toxicities included stomatitis, ataxia, and bone marrow aplasia. Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response. In vitro studies demonstrated P-glycoprotein expression on the blasts of 5 of 14 patients, although only 1 had inhibition of rhodamine efflux by valspodar. CONCLUSIONS: While this regimen was tolerable, responses in this heavily pretreated population were limited to a subset of patients with ALL.
Authors: Roland B Walter; Ted A Gooley; Vincent H J van der Velden; Michael R Loken; Jacques J M van Dongen; David A Flowers; Irwin D Bernstein; Frederick R Appelbaum Journal: Blood Date: 2007-01-16 Impact factor: 22.113
Authors: I Chico; M H Kang; R Bergan; J Abraham; S Bakke; B Meadows; A Rutt; R Robey; P Choyke; M Merino; B Goldspiel; T Smith; S Steinberg; W D Figg; T Fojo; S Bates Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: N J Lacayo; B L Lum; D L Becton; H Weinstein; Y Ravindranath; M N Chang; L Bomgaars; S J Lauer; B I Sikic; G V Dahl Journal: Leukemia Date: 2002-05 Impact factor: 11.528
Authors: Catharina Dhooge; Barbara De Moerloose; Geneviève Laureys; Alice Ferster; Dirk De Bacquer; Jan Philippe; Jules Leroy; Yves Benoit Journal: Leuk Lymphoma Date: 2002-02
Authors: G Visani; D Milligan; F Leoni; J Chang; S Kelsey; R Marcus; R Powles; S Schey; A Covelli; A Isidori; M Litchman; P P Piccaluga; H Mayer; M Malagola; C Pfister Journal: Leukemia Date: 2001-05 Impact factor: 11.528
Authors: M L Linenberger; T Hong; D Flowers; E L Sievers; T A Gooley; J M Bennett; M S Berger; L H Leopold; F R Appelbaum; I D Bernstein Journal: Blood Date: 2001-08-15 Impact factor: 22.113
Authors: P Sonneveld; A Burnett; P Vossebeld; M Ben-Am; G Rosenkranz; C Pfister; G Verhoef; A Dekker; G Ossenkoppele; C Ferrant; L Yin; A Gratwohl; T Kovacsovics; E Vellenga; R Capdeville; B Löwenberg Journal: Hematol J Date: 2000
Authors: K Naito; A Takeshita; K Shigeno; S Nakamura; S Fujisawa; K Shinjo; H Yoshida; K Ohnishi; M Mori; S Terakawa; R Ohno Journal: Leukemia Date: 2000-08 Impact factor: 11.528
Authors: Judith M Chessells; Paul Veys; Helena Kempski; Patricia Henley; Ali Leiper; David Webb; Ian M Hann Journal: Br J Haematol Date: 2003-11 Impact factor: 6.998
Authors: Michaela Liedtke; Clare J Twist; Bruno C Medeiros; Jason R Gotlib; Caroline Berube; Marcia M Bieber; Neelima M Bhat; Nelson N Teng; Steven E Coutre Journal: Haematologica Date: 2011-10-11 Impact factor: 9.941
Authors: X Yang; P Yang; J Shen; E Osaka; E Choy; G Cote; D Harmon; Z Zhang; H Mankin; F J Hornicek; Z Duan Journal: Br J Cancer Date: 2014-05-22 Impact factor: 7.640
Authors: Mei Lan Chen; Amy Sun; Wei Cao; Amber Eliason; Kayla M Mendez; Adam J Getzler; Shanel Tsuda; Huitian Diao; Clever Mukori; Nelson E Bruno; Sang Yong Kim; Matthew E Pipkin; Sergei B Koralov; Mark S Sundrud Journal: J Exp Med Date: 2020-05-04 Impact factor: 14.307